Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease

Genetic Testing

Volumn 10, Issue 3, 2006, Pages 221-227

  Kay, Denise M ^a   Bird, Tom D ^b   Zabetian, Cyrus P ^b   Factor, Stewart A ^c,d   Samii, Ali ^e   Higgins, Donald S ^d   Nutt, John ^f   Roberts, John W ^g   Griffith, Alida ^h   Leis, Berta C ^h   Montimurro, Jennifer S ^a   Philpott, Sean ^a,i   Payami, Haydeh ^a,i  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h Evergreen Hospital Medical Center   (United States)

ⁱ Alden March Bioethics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; SERINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ECONOMIC ASPECT; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE DETECTION; HUMAN; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUTATIONAL ANALYSIS; ONSET AGE; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEX DIFFERENCE; SOCIAL ASPECT; STATISTICAL MODEL; TASK PERFORMANCE; UNITED STATES; VALIDITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; FEMALE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY;

EID: 33845210839     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2006.10.221     Document Type: Article

References (42)

1. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR and Farrer M (2005) Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57:762-765.
2. Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E, Dekker M, Squitieri F, Ibanez P, Joosse M, van Dongen J, Vanacore N, van Swieten J, Brice A, Meco G, van Duijn C, Oostra B and Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259.
3. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M and Vanacore N (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. The Lancet 365:412-415.
4. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA and Bonifati V (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14:322-331.
5. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ and Rocca WA (2002) Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55:25-31.
6. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F and Tolosa E (2006) LRRK2 mutations in Spanish patients with parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63:377-382.
7. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V and Quinn NP (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. The Lancet 365:415-416.
8. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G and Bonifati V (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42:e65.
9. Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, GwinnHardy K, Dickson D, Wavrant Devrieze F, Hardy J and Singleton A (2005) The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389:137-139.
10. Hughes A, Daniel S, Kilford L and Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's Disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
11. Hughes AJ, Daniel SE and Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57:1497-1499.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y and Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861-870.
13. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ and Toft M (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
14. Kay DM, Kramer P, Higgins D, Zabetian CP and Payami H (2005) Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 20:1077-1078.
15. Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, Bird TD, Kramer P, Higgins DS and Payami H (2006) Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 21:519-523.
16. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB and Wood NW (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796.
17. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y and Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
18. Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG and Vassilatis DK (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nature Genet 33:85-89.
19. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD and Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
20. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, Durr A and Brice A (2005a) G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58:784-787.
21. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A and Brice A (2005b) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330-332.
22. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P and Brice A (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354:422-423.
23. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi K, Shults C and Wenning GK (2003) SIC Task Force Appraisal of Clinical Diagnostic Criteria for Parkinsonian Disorders. Movement Disorders 18:467-486.
24. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y and Brice A (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 342:1560-1567.
25. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857-872.
26. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A and Shults CW (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. The Lancet 365:410-412.
27. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N and Bressman SB (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354:424-425.
28. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, de Munanin AL, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, MartiMasso JF, Perez-Tur J, Wood NW and Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's Disease. Neuron 44:1-12.
29. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A and Rogaeva E (2005) LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65:696-700.
30. Paulson GW and Prior TW (1997) Issues related to DNA testing for Huntington's disease in symptomatic patients. Semin Neurol 17:235-238.
31. Payami H, Zareparsi S, James D and Nutt J (2002) Familial aggregation of Parkinson disease - a comparative study of early-onset and late-onset disease. Arch Neurol 59:848-850.
32. Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos E, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson W, Lazzarini A, Duvoisin R, Di Iorio G, Golbe L and Nussbaum R (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
33. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ and Dickson DW (2006) Lrrk2 and Lewy body disease. Ann Neurol 59:388-393.
34. Steinbart EJ, Smith CO, Poorkaj P and Bird TD (2001) Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 58:1828-1831.
35. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L and Liu JJ (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 384:327-329.
36. Tanner CM and Goldman SM (1996) Epidemiology of Parkinson's disease. Neurol Clin 14:317-335.
37. Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO and Farrer MJ (2005) LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 126:1201-1205.
38. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G and Wood NW (2004) Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1. Science 304:1158-1160.
39. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH and Griffith A (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65:741-744.
40. Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD and Payami H (2006a) Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. Arch Neurol 63:156-157.
41. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor A, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A and Payami H (2006b) LRRK2 G2019S in families with Parkinson's disease originating from Europe and the Middle East: Evidence for two distinct founding events beginning two millennia ago. Am J Hum Genet [ePub ahead of print].
42. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek Z and Gasser T (2004) Mutations in LRRK2 cause autosomal dominant Parkinsonism with pleomorphic pathology. Neuron 44:601-607.